**Specifications table**TableSubject area*Genetics*More specific subject area*Seizures*Type of data*Table*How data was acquired*Next-generation sequencing, clinical data*Data format*Analyzed*Experimental factors*Sample was peripheral blood*Experimental features*SCN1A and SCN2A variants were identified by next-generation sequencing. Variants which assumed to be pathogenic were identified.*Data source location*Shanghai, China*Data accessibility*Data are available in this article*

**Value of the data**•The data identify novel mutations in sodium channel SCN1A and SCN2A genes.•The data show the difference of EEGs and prognosis between *SCN1A* and *SCN2A* mutations.•The data might be useful for further function experiments in cellular and animal levels.

1. Data {#s0005}
=======

Mutations in genes encoding the voltage-gated sodium channel are associated with seizure-related syndromes. Different genes or different mutations in the same gene have distinct phenotypes [@bib1], [@bib2]. Clinical features and mutations of SCN1A and SCN2A genes are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Table 1Summary of the clinical features of subjects with a *SCN1A* mutation.Table 1Patient12345SexMFMMFhistory of pregnancy and deliveryasphyxianormalnormalnormalnormalFamily historyNA(--)(--)(--)(--)Diagnosisneonatal seizureneonatal seizureDravet synepilepsyDravet synMutationNM_001165963:exon11:c.1978C\>A(p.P660T), NANM_001165963:exon11:c.1888C\>T(p.R630W), paternalNM_001165963:exon15:c.2825_2826insT,NANM_001165963:exon3:c.437 C\>G(p.T146R) *de novo*NM_001165963:exon15:c.2927 T\>A(p.M976K) *de novo*HGMDNYNNNAge at onset1 d24 d4 m5 m3 mInitial epileptic attacksNAtonic sztonic-clonic without fevertonic-clonic without feverfocal seizureFrequency of initial szNA1/d1 /m1/2 m5/10dTransition to other szNAnotonic-clonic with/without fever, SEtonic-clonic without fever, SEtonic-clonic with fever, SEInitial EEG, ageNAfrontal sharp wave and sharp and slow wave complexnormalnormalnormalEEG follow upNAnormal(3 m)normalleft frontal sharp and slow wave complex(2 y)central sharp and slow wave complex and spike and slow wave complex(5 m)MRI findingscorpus callosum and cerebellar hypoplasianormalCompression of the cerebellumFull lateral ventriclesnormaldrugsNAnoVPA+TPM, OXC, LTGVPA+TPM, LEVVPA+TPMSz prognosisNAno szseizure reductionseizure reductionseizure reductionDevelopmentNAnormal(1 y)severe developmental delay(6 y)normal(3 y)mild developmental delay(2 y)Patient678910SexMMFFFhistory of pregnancy and deliveryNANAnormalnormalnormalFamily historyNAgrand-uncle(--)(--)(--)DiagnosisFS+epilepsyDravet synFS+Dravet synMutationNM_001165963:exon2:c.274 G\>C(p.V92L),NANM_001165963:exon23:c.4385_4389delACTTT,NANM_001165963:exon10:c.1400 C\>G(p.S467X), *de novo*NM_001165963:exon15:c.2839 G\>T(p.V947L),*de novo*NM_001165963:exon26:c.4985_4989delCTTTG, NAHGMDNNNNNAge at onset8 m11 m3 m4 m7 mInitial epileptic attackstonic-clonic with fever,SEfocal seizurefocal seizurefocal seizuretonic-clonicFrequency of initial sz5/6 m4/4 mseveral times/d1 /m1 /mTransition to other sztonic-clonic with/without feverNAtonic-clonic with/without fever; myoclonusNAtonic-clonic,SEInitial EEG, ageNANAleft temporal sharp wave and sharp and slow wave complexsharp wave and sharp and slow wave complex in the right frontRight temporal occipital sharp wave and spike waveEEG follow upnormalNAnormalNANAMRI findingsnormalNAnormalnormalnormaldrugsVPA, LEVVPAVPA+LEV+TPM, ketogenic dietVPA+LEV+LTG, TPMVPA+TPM+LEVSz prognosisseizure freeNAseizure reductionseizure reductionseizure reductionDevelopmentnormal(4 y)NAsevere developmental delay(21 m)normal(4 y)mild developmental delay(22 m)Patient1112131415SexMFMFFhistory of pregnancy and deliverynormalnormalasphyxianormalNAFamily historymother, aunt(--)(--)fatherNADiagnosisDravet synDravet synDravet synGEFS+epilepsyMutationNM_001165963:exon14:c.2589+2 T\>A, NANM_001165963:exon8:c.1150 T\>C(p.W384R),NANM_001165963:exon14:c.2573 T\>C(p.L858P), *de novo*NM_001165963:exon26:c.5020 G\>A(p.G1674S),NANM_001165963:exon23:c.4348 C\>T(p.Q1450X) *de novo*HGMDNYNYNAge at onset6 m3 m1 m8 m\<1 yInitial epileptic attackstonic-clonicfocal seizurefocal seizuretonic-clonic with feverNAFrequency of initial sz3 /m1/2--3 m2--3/d4--5/yNATransition to other sztonic-clonic with/without fever;focal seizurenotonic-clonic without fevernoNAInitial EEGspike wave and spike and slow wave complex in the left central-occipitalnormalmultifocal sharp wave, spike wave and sharp and slow wave complexparietal-occipital spike wave and sharp waveNAEEG follow upnormal(1y9m)normal(5 m)multifocal sharp wave, spike wave and sharp and slow wave complexnormal(6 y)NAMRI findingsarachnoid cystcerebral dysplasia,thin corpus callosumcerebral atrophy,thin corpus callosumCT:normalNAdrugsVPA+LEVVPA+LEVVPA+TPM+LEV, OXC, CZPOXC, LEVVPA+TPMSz prognosisseizure reductionseizure reductionseizure reductionseizure free after LEVNADevelopmentmild developmental delay(3 y)mild developmental delay(2 y)severe developmental delay(3 y)normal(9 y)NAPatient1617181920SexMMMFMhistory of pregnancy and deliveryasphyxianormalNAnormalnormalFamily history(--)(--)(--)(--)great-uncleDiagnosisDravet synDravet synFS+FS+Dravet synMutationNM_001165963:exon24:c.4529 C\>T(p.A1510V), *de novo*NM_001165963:exon16:c.2948delC, *de novo*NM_001165963:exon26:c.5347 G\>A(p.A1783T), NANM_001165963:exon26:c.5183 G\>A(p.G1728E) *de novo*NM_001165963:exon10:c.1662G\>A(p.Q554Q), *de novo*HGMDNNYNYAge at onset3 m6 m5 m7 m5 mInitial epileptic attackstonic-clonic without feverfocal seizuretonic-clonic with fevertonic-clonic without fevertonic with feverFrequency of initial sz1/1 mNA2--3 /m2/d1--2 /mTransition to other szfocal seizuretonic-clonic with feverNAtonic-clonic with fevertonic-clonic without feverInitial EEGmultifocal sharp wave and sharp and slow wave complexnormaloccipital spike wave and spike and slow wave complexnormalNAEEG follow upmultifocal sharp wave and sharp and slow wave complex(15 m)cental spike waveNAmultifocal sharp wave(22 m)occipital spike wave and spike and slow wave complexMRI findingsthin corpus callosumnormalnormalnormalAbnormal signal of left frontal lobedrugsLEV+VPA+TPMOXC, VPA+TPM+LEV, CZPVPA+LEVVPA, OXC,LEVVPA+LEV+TPM, OXCSz prognosisseizure reductionseizure freeno effectseizure freeno effectDevelopmentsevere developmental delay(2 y)severe developmental delay(4 y)NAnormal(28 m)severe developmental delay(12 y)Patient2122232425SexFMMFMhistory of pregnancy and deliverynormalnormalnormalnormalnormalFamily history(--)(--)mother(--)(--)DiagnosisepilepsyFS+Dravet synepilepticepilepsyMutationNM_001165963:exon13:c.2351_2351delinsCTTAAATACTCTTTT, *de novo*NM_001165963:exon21:c.4083 C\>A(p.F1361L), *de novo*NM_001165963:exon15:c.2831_2832delGT, *de novo*NM_001165963:exon11:c.2039 A\>G(p.D680G),NANM_001165963:exon1:c.82 C\>T(p.R28C),NAHGMDNNNNYAge at onset6 m10 m3 m5 y2 yInitial epileptic attacksfocal seizuretonic-clonic with feverclonic with fever, SEfocal seizuretonic-clonic with feverFrequency of initial sz2/d-1/3 m7--8/yNA1 /mNATransition to other sztonic-clonic with/without fevernotonic-clonic with fever, focal seizuretonic-clonicnoInitial EEG, agenormalmultifocal sharp waveNANANAEEG follow upmultifocal sharp wave spike wave, sharp and slow wave complex and spike and slow wave complex(11 m)occipital spike wave and spike and slow wave complex(7 y)spike wave and spike and slow wave complexoccipital spike wave and spike and slow wave complex(12 y)NAMRI findingsdelayed myelinationnormalNAnormalNAdrugsVPA+LEVVPA+LEV+TPMVPA+TPM, OXC, CZPTPM, CBZnoSz prognosisno effectseizure freeseizure reductionno effectseizure freeDevelopmentnormal(15 m)normal(7 y)severe developmental delay(7 y)NAnormal(5 y)Patient2627282930SexFFFMFhistory of pregnancy and deliverynormalNAnormalnormalnormalFamily historymotherNA(-)Grand-uncle(-)DiagnosisGEFS+Dravet synepilepsyGEFS+Dravet synMutationNM_001165963:exon21:c.4009 G\>A(p.V1337M),NANM_001165963.1:exon14:c.2589+3 A\>T, *de novo*NM_001165963:exon11:c.1738C\>T(p.R580X),*de novo*NM_001165963:exon2:c.301 C\>T(p.R101W),NANM_001165963:exon11:c.2021 A\>G(p.D674G), NAHGMDNYYYYAge at onset18 m6 m2 m3 m6 mInitial epileptic attackstonic-clonic with fevertonic-clonictonic without fevertonic-clonic with feverfocal seizureFrequency of initial sz2/3 yNA2 /m1 /mNATransition to other szNANAtonic-clonic, focal seizures,SEnonoInitial EEG, ageNAnormalnormalnormalnormalEEG follow upNAnormalspike wave and spike and slow wave complex(6 m)multifocal spike wave and spike and slow wave complexnormalMRI findingsNANAnormalnormalnormaldrugsnoVPA+LEVLEV+TPM, OXCVPA+LEVVPA+TPM+CZP, LEVSz prognosisseizure freeseizure freeseizure reductionno effectseizure reductionDevelopmentNAmild developmental delay(9 y)normal(1 y)normal(2 y)severe developmental delay(3 y)Patient313233SexMMMhistory of pregnancy and deliverynormalNAnormalFamily historyfatherNA(-)DiagnosisGEFS+epilepsyDravet synMutationNM_001165963:exon26:c.5293 T\>A(p.F1765I), paternalNM_001165963:exon25:c.4633 A\>G(p.I1545V), *de novo*NM_001165963:exon21:c.4143delT(p.G1382Vfs⁎9),NAHGMDNYNAge at onset14 m3 m6 mInitial epileptic attackstonicfocal seizuretonicFrequency of initial szNANA1--2 /mTransition to other szfocal seizurestonic-clonicfocal seizures, SEInitial EEGabnormalabnormalmultifocal sharp wave and sharp and slow wave complexEEG follow upnormalabnormalmultifocal sharp wave, spike wave, sharp and slow wave complexand spike and slow wave complex(15 m)MRI findingsarachnoid cystnormalnormaldrugsVPAVPA+LEV, OXC, ketogenic dietVPA, ketogenic dietSz prognosisseizure freeno effectseizure reductionDevelopmentNAnormal(6 y)mild developmental delay(18 m)[^2]Table 2Summary of the clinical features of subjects with a *SCN2A* mutation.Table 2Patient3435363738SexMMFMFhistory of pregnancy and deliverynormalasphyxianormalnormalnormalFamily history(-)(-)(-)uncle(-)Diagnosisneonatal seizureneonatal seizureepileptic encephalopathyepilepsyepilepsyMutationNM_021007:exon26:c.4751 C\>G(p.S1584C),NANM_021007:exon27:c.4918 A\>T(p.I1640F),NANM_021007:exon7:c.781 G\>A(p.V261M), *de novo*NM_021007:exon17:c.2989 G\>T(p.D997Y), *de novo*NM_021007:exon27:c.4886 G\>A(p.R1629H),NAHGMDNNYNNAge at onset3d7d4d1d1dInitial epileptic attacksclonicclonictonic-clonicclonictonicFrequency of initial szNAfrequentlyfrequently6--7/d1/dTransition to other szNANAnotonic-clonictonic-clonicInitial EEG, ageleft frontal-parietal sharp wave,spike wave and sharp and slow wave complexslow wavemultifocal spikeand slow wave complex and sharp and slow wave complexsuppression-burstslow waveEEG follow upNANANANANAMRI findingsnormalbilateral parietal,occipital and basal ganglia region injury, myelination delayednormalnormalcystic change of the body of lateral ventricledrugsphenobarbitalphenobarbital, VPA+LEVphenobarbital, LEVphenobarbital, LEV+TPMVPA+LEVSz prognosisseizure freeno effectseizure freeseizure freeseizure freeDevelopmentNANAsevere developmental delaysevere developmental delaynormalPatient3940414243SexFMMMMhistory of pregnancy and deliverynormalnormalnormalnormalnormalFamily history(-)(-)(-)(-)(-)Diagnosisneonatal seizureneonatal seizureepileptic encephalopathyepileptic encephalopathyepilepsyMutationNM_021007:exon2:c.106 A\>G(p.R36G),NANM_021007:exon16:c.2670 C\>G(p.I890M),NANM_021007:exon15:c.2558 G\>A(p.R853Q), *de novo*NM_021007:exon27:c.4886 G\>A(p.R1629H), *de novo*NM_021007:exon21:c.3961 G\>A(p.E1321K), *de novo*HGMDNNYNYAge at onset2d1d7 m1 m3dInitial epileptic attacksclonicfocal seizureseyelid myoclonusfocal seizureseyelid myoclonus, tonic-clonicFrequency of initial sz3--5/d5--8/dNANA7--8/dTransition to other szNANAspasms, tonic-clonicspasmsNAInitial EEG, agemultifocal sharp wave and sharp and slow wave complexmultifocal spikeand slow wave complex and sharp and slow wave complexmultifocal spikeand slow wave complex and sharp and slow wave complexmultifocal spikeand slow wave complex and sharp and slow wave complexmultifocal spikeand slow wave complex and sharp and slow wave complexEEG follow upNANANANAnormalMRI findingsnormalnormalcerebral dysplasia and thin corpus callosumthin corpus callosumthin corpus callosumdrugsNANACBZ+VPA+ mexiletineVPA+LEV, OXC, CZPVPA+LEV+TMPSz prognosisseizure freeseizure freeno effectno effectseizure freeDevelopmentNANAsevere developmental delaysevere developmental delaynormalPatient4445464748SexMMFFMhistory of pregnancy and deliverynormalnormalnormalnormalNAFamily history(-)mother, elder sister(-)(-)NADiagnosisepileptic encephalopathyBFISepilepsyepileptic encephalopathyepilepsyMutationNM_021007:exon27:c.5616 G\>A(p.M1872I), *de novo*NM_021007:exon2:c.209 C\>T(p.P70L),NANM_021007:exon19:c.3524 G\>A(p.C1175Y),NANM_021007:c.3521--2 A\>G, *de novo*NM_021007:exon27:c.5045 T\>C(p.F1682S), *de novo*HGMDNNNNNAge at onset3 m1 y4 y19 m7 yInitial epileptic attackstonicatonic seizuretonictonic-clonicNAFrequency of initial sz7/10d4/dNANANATransition to other szNANAatonic seizuresNANAInitial EEGNAabnormalmultifocal spikeand slow wave complex and sharp and slow wave complexepileptiform dischargeNAEEG follow upnormalnormalNAnormalNAMRI findingsnormalNAnormalnormalNAdrugsVPA, LEVnoVPAVPA+TPMCBZSz prognosisseizure freeseizure freeseizure freeseizure reductionseizure freeDevelopmentdevelopmental delaynormalsevere developmental delaydevelopmental delaydevelopmental delay[^3]

2. Experimental design, materials and methods {#s0010}
=============================================

Eight hundred and twenty-two children with epilepsy or neonatal severe seizures were performed whole exome sequencing (WES) or clinical exome sequencing (focused 2742 genes). We extracted genomic DNA in the peripheral blood of the children. DNA fragments were enriched for whole exome sequencing using the Agilent (Santa Clara, CA, USA) SureSelectXT Human All Exon 50 Mb kit, and for panel sequencing using the Agilent (Santa Clara, CA, USA) ClearSeq Inherited Disease panel kit. Our own database and public databases including the exome aggregation consortium, the 1000 Genome Project, and the dbSNP137 reported in the UCSC Genome Browser were used to screen the variants. Pathogenic variants or likely pathogenic variants were considered to be candidate variants. The candidate variants were validated by Sanger sequencing. *SCN1A* or *SCN2A* mutations were recruited in the database. Clinical information including sex, birth history, family history, seizure onset, seizure types, frequency of seizures, initial and follow-up EEGs, brain MRI findings, antiepileptic drugs, prognosis and developmental data were collected.
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[^1]: These authors contributed equally to this work.

[^2]: Dravet syn: Dravet syndrome, FS+: febrile seizures plus, GEFS+: Generalized epilepsy with febrile seizures plus, VPA: valproate, LEV: levetiracetam, TPM: Topamax, CBZ: carbamazepine, CZP: clonazepam, OXC: oxcarbazepine; sz: seizure(s), SE: status epilepticus.

[^3]: VPA: valproate, LEV: levetiracetam, TPM: Topamax, CBZ: carbamazepine, CZP: clonazepam, OXC: oxcarbazepine, sz: seizure(s), SE: status epilepticus.
